Analysts expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to post sales of $23.01 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Seres Therapeutics’ earnings, with estimates ranging from $23.00 million to $23.02 million. Seres Therapeutics posted sales of $13.02 million in the same quarter last year, which suggests a positive year-over-year growth rate of 76.7%. The firm is expected to announce its next quarterly earnings report on Thursday, November 9th.

On average, analysts expect that Seres Therapeutics will report full year sales of $23.01 million for the current financial year, with estimates ranging from $29.04 million to $32.00 million. For the next year, analysts anticipate that the company will post sales of $19.53 million per share, with estimates ranging from $12.00 million to $27.06 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.10. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The firm had revenue of $3 million for the quarter, compared to the consensus estimate of $3 million. During the same period in the previous year, the business earned ($0.70) EPS. The firm’s revenue was up .0% compared to the same quarter last year.

MCRB has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Wednesday, July 5th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a research report on Friday, May 19th. Canaccord Genuity set a $20.00 target price on shares of Seres Therapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, HC Wainwright reissued a “buy” rating and set a $19.00 target price (up previously from $15.00) on shares of Seres Therapeutics in a research report on Friday, August 4th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $17.00.

Seres Therapeutics (NASDAQ MCRB) traded up 0.56% on Monday, reaching $14.44. 26,597 shares of the company traded hands. The firm has a 50 day moving average of $13.62 and a 200-day moving average of $11.21. Seres Therapeutics has a one year low of $8.85 and a one year high of $15.09. The stock’s market capitalization is $584.99 million.

Hedge funds have recently made changes to their positions in the company. Teachers Advisors LLC lifted its holdings in shares of Seres Therapeutics by 43.5% in the 4th quarter. Teachers Advisors LLC now owns 41,101 shares of the biotechnology company’s stock worth $407,000 after purchasing an additional 12,462 shares in the last quarter. Bank of Montreal Can lifted its holdings in shares of Seres Therapeutics by 33.7% in the 1st quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 4,829 shares in the last quarter. American Century Companies Inc. bought a new position in shares of Seres Therapeutics in the 1st quarter worth $447,000. Parametric Portfolio Associates LLC lifted its holdings in shares of Seres Therapeutics by 1.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock worth $240,000 after purchasing an additional 279 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Seres Therapeutics by 15.9% in the 1st quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock worth $4,172,000 after purchasing an additional 50,860 shares in the last quarter. 74.76% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/11/analysts-anticipate-seres-therapeutics-inc-mcrb-will-post-quarterly-sales-of-23-01-million.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.